ArticleBMC cancer2022

High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.

Liru Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.